This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B23.2 (Hematological and immunological abnormalities) | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | HIV-related hematological abnormalities; HIV-related immunological abnormalities; HIV-associated cytopenias; HIV-associated immune dysregulation |
| C. Adult onset | Likelihood of adult onset: very high — B23.2 is the code applied when various hematological and immunological abnormalities occur because of HIV infection, such as decreased CD4+ T cells, pancytopenia (anemia, leukopenia, thrombocytopenia), hypergammaglobulinemia, and elevated immune activation markers. In HIV-infected adults, these abnormalities appear to varying degrees at all clinical stages. |
| 1. History | Since the first description of AIDS in 1981, CD4 lymphocyte depletion has been recognized as the core of the immune defect. HIV-associated ITP (immune thrombocytopenia) described in the 1980s. Hematological abnormalities used as prognostic indicators in HIV. CD4 count measurement established as the standard indicator in clinical management of HIV. |
| 2. Causes | Direct infection and destruction of CD4+ T cells by HIV. Autoantibody production through HIV molecular mimicry (ITP, AIHA). Cytopenias from direct bone marrow infection and cytokine suppression. Bone marrow toxicity of ART drugs. Bone marrow involvement by opportunistic infections (MAC, CMV). |
| 3. Genetics | Not a hereditary disease. HLA type influences the tendency to autoantibody production (ITP, AIHA). Erythropoietin receptor and thrombopoietin polymorphisms influence the severity of HIV-associated anemia and thrombocytopenia. |
| 4. General epidemiology | Anemia: occurs in 30–80% of HIV-infected individuals. Thrombocytopenia (including ITP): 5–40%. Leukopenia/neutropenia: 5–25%. Hypergammaglobulinemia: in many asymptomatic HIV-infected individuals. CD4 decline: in all patients at HIV diagnosis, to varying degrees. |
| 5. Pathophysiology | Direct destruction of CD4+ T cells (HIV gp120 binding, syncytia formation, apoptosis). Bone marrow suppression (HIV Vpr, TNF-α, IL-1β). Molecular mimicry autoantibodies (platelet and red cell surface molecules). Infection of hematopoietic stem cells. ART drug toxicity (e.g., bone marrow suppression by zidovudine). |
| 6. Symptoms | Anemia: fatigue, dyspnea, pallor. Thrombocytopenia: petechiae, purpura, excessive bleeding. Immunodeficiency: recurrent infections, opportunistic infections. Hypergammaglobulinemia: mostly asymptomatic. Lymphopenia: increased risk of opportunistic infection. |
| 7. Signs | Pale conjunctivae and oral mucosa (anemia). Petechiae, purpura, bleeding (thrombocytopenia). Skin infections, oral candidiasis (immunodeficiency). Blood: decreased CD4, decreased Hb, decreased platelets, hypergammaglobulinemia, positive HIV RNA. |
| 8. Screening | In all HIV-infected individuals: regular complete blood count (CBC), CD4/CD8 lymphocyte counts, quantitative HIV RNA. Evaluate the cause of anemia (iron, vitamin B12, folate, erythropoietin). Antiplatelet antibody testing if thrombocytopenia. |
| 9. Diagnosis | Confirmation of HIV infection + definitive diagnosis of each hematological/immunological abnormality. CD4 <200/μL: confirms immunodeficiency. Platelets <100×10⁹/L: assess for HIV-associated ITP. Anemia: classify cause (normocytic, microcytic, macrocytic). Bone marrow examination (when opportunistic infection involving the marrow is suspected). |
| 10. Treatment | ART initiation (immune recovery and improvement of cytopenias). Anemia: erythropoietin, iron supplementation. HIV-associated ITP: IVIG, corticosteroids, eltrombopag, rituximab. Neutropenia: G-CSF. In severe thrombocytopenia, switch ART drugs (especially avoid zidovudine). |
| 11. Prognosis | In patients responding to ART, hematological abnormalities mostly improve. Anemia is an independent prognostic factor in AIDS (the more anemia, the higher the risk of death). Thrombocytopenia mostly improves after ART. Severe immunodeficiency (CD4 <50) has a poor prognosis. |
| 12. Prevention | Prevent CD4 decline through early HIV diagnosis and ART. Avoid bone-marrow-toxic ART drugs (zidovudine) whenever possible. Maintain nutritional status (iron, vitamin B12, folate). Prevent secondary bone marrow involvement by preventing opportunistic infections. |
| 13. References | Includes 10 key references |
Hematological and immunological abnormalities related to HIV were recognized as core clinical features from the early days of the AIDS epidemic. In AIDS patients first described by the CDC in 1981, marked depletion of CD4+ T lymphocytes was observed, and this was identified as the direct cause of immune vulnerability to opportunistic infections and malignancies.
In 1982, HIV-associated thrombocytopenia, particularly immune thrombocytopenic purpura (ITP), was described. Abrams et al. reported that autoantibodies against platelets were detected in HIV-infected patients and that platelet destruction was increased. This was recognized as a new mechanism by which HIV induces an autoimmune response against platelets.
In the mid-1980s, the CD4+ T lymphocyte count was established as the key test reflecting the immune status in HIV infection. In 1987 the CDC included the CD4 count in the classification of HIV infection and began classifying patients by degree of immunosuppression. Subsequently CD4 <200/μL was adopted as the criterion for AIDS-defining immunodeficiency (CDC 1993).
In the late 1980s, the pathophysiology of HIV-associated anemia was clarified. Anemia of chronic disease, reduced response to erythropoietin, bone marrow suppression, and bone marrow toxicity from zidovudine (AZT) were presented as the main mechanisms of anemia. Administration of erythropoietin (EPO) began to be studied as a treatment for HIV-associated anemia.
From the 1990s onward, the importance of HIV-associated immune activation and chronic immune dysregulation came to the fore. Beyond simple CD4 depletion, it was revealed that the chronic immune activation that persists in HIV infection (increased CD38+HLA-DR+ CD8+ T cells, elevated sCD14, etc.) is a key mechanism of non-AIDS complications such as cardiovascular disease, kidney disease, and neurodegeneration. As a result, HIV infection was reconceptualized as a disease of "immune dysregulation" and not only "immunodeficiency."
Hematological and immunological abnormalities related to HIV result from the combined action of direct effects of HIV, immune-mediated mechanisms, and secondary effects of opportunistic infections and drugs.
Mechanism of CD4+ T-cell depletion: HIV enters CD4+ T cells using the CD4 molecule and the CCR5 or CXCR4 co-receptor. Infected cells form syncytia through the interaction of HIV gp120 with cell-surface CD4, destroying uninfected CD4+ T cells on a large scale. The HIV Vpr protein induces apoptosis of CD4+ T cells. Activation-induced cell death (AICD) due to persistent immune activation also accelerates CD4 loss.
Mechanisms of anemia: (1) Anemia of chronic disease: proinflammatory cytokines (IL-6, TNF-α, IL-1β) induce hepcidin synthesis, causing impaired iron utilization. (2) Hyporesponsiveness to erythropoietin (EPO): in HIV infection, EPO secretion is inappropriately low for the degree of anemia. (3) Direct bone marrow suppression: HIV Vpr suppresses proliferation of hematopoietic progenitor cells. TNF-α inhibits erythroid colony formation. (4) Bone marrow toxicity of zidovudine (AZT): impaired erythroblast maturation due to inhibition of mitochondrial DNA polymerase γ. (5) Nutritional deficiency: iron, vitamin B12, and folate deficiency worsen anemia.
Mechanism of thrombocytopenia (ITP): HIV molecular mimicry: structural similarity between HIV gp120 and the platelet surface GPIIb/IIIa leads to production of antiplatelet autoantibodies. Immune complexes (HIV antigen + IgG) bind to platelet Fc receptors, promoting platelet destruction by splenic macrophages. Decreased megakaryocytes: HIV directly infects megakaryocytes, impairing platelet production. Bone marrow suppression by drugs such as TMP-SMX (PCP prophylactic) and ganciclovir also contributes.
Immune activation and dysregulation: abnormal activation of T cells and B cells persists in chronic HIV infection. Chronic activation of CD8+ T cells (CD38+HLA-DR+ phenotype) accelerates immune aging. Polyclonal activation of B cells causes hypergammaglobulinemia, while functional B-cell responses are reduced. Microbial products (LPS) from bacterial translocation continuously stimulate the immune system through TLRs, maintaining chronic immune activation.
The hematological and immunological abnormalities classified under B23.2 are not hereditary diseases, but various host genetic factors influence the susceptibility to and severity of each hematological abnormality.
HLA and autoimmune thrombocytopenia: HLA-DR4 and HLA-DR7 alleles carry a genetic predisposition associated with the development of immune thrombocytopenia (ITP). In HIV-associated ITP as well, these HLA alleles may increase the tendency to produce antiplatelet autoantibodies. HIV-associated autoimmune phenomena are reported more commonly in carriers of HLA-DRB1*03 and DRB1*04.
Erythropoietin receptor polymorphism: polymorphisms of the EPOR (erythropoietin receptor) gene influence the responsiveness of erythroid progenitor cells to EPO. Some EPOR polymorphisms cause hyporesponsiveness to EPO and may affect the severity of HIV-associated anemia and the response to EPO treatment.
Thrombopoietin (TPO)-related genes: MPL (TPO receptor) polymorphisms affect megakaryocyte proliferation and platelet production capacity. THPO (thrombopoietin gene) polymorphisms may contribute to determining the severity of HIV-associated thrombocytopenia.
Immune regulatory genes: FoxP3 gene polymorphisms affect regulatory T-cell (Treg) function and thereby modulate the tendency toward autoimmunity and the degree of immune dysregulation in HIV infection. PTPN22 gene polymorphisms determine the T-cell activation threshold and may influence the occurrence of autoimmune hematological abnormalities.
Hematological and immunological abnormalities related to HIV occur at all stages of HIV infection and are closely related to the degree of immunosuppression.
Anemia: the most common hematological abnormality in HIV-infected individuals. In pre-ART studies, the prevalence of anemia (Hb <12 g/dL; women <11 g/dL) was 70–80% in AIDS patients and 30–40% in asymptomatic HIV-infected individuals. Prevalence decreased after the introduction of ART, but anemia persists in 20–30% of all HIV-infected individuals even during ART treatment. Macrocytic anemia is common in patients using zidovudine (AZT).
Thrombocytopenia: thrombocytopenia (platelets <150×10⁹/L) has a prevalence of 5–40% in HIV-infected individuals. Prevalence is higher at the AIDS stage. The prevalence of HIV-associated ITP is 3–8%, markedly higher than in the general population (0.01%). Prevalence decreased after the introduction of ART.
Leukopenia/neutropenia: leukopenia (<4,000/μL) occurs in 5–25% of HIV-infected individuals. Neutropenia (<1,500/μL) is especially common with drugs such as AZT, TMP-SMX, and ganciclovir. Severe neutropenia with neutrophils <500/μL markedly raises the risk of bacterial infection.
Hypergammaglobulinemia: in about 50–70% of HIV-infected individuals, polyclonal hypergammaglobulinemia with simultaneous elevation of serum IgG, IgA, and IgM is observed. This reflects nonspecific polyclonal B-cell activation by HIV. Immunoglobulin levels normalize to some extent after ART.
CD4+ T-cell depletion: in untreated HIV-infected individuals, CD4+ T cells decline by about 50–100/μL per year. CD4 <200/μL is AIDS-defining immunodeficiency, and from this point the risk of opportunistic infection rises sharply. CD4 recovery is possible in most patients with ART, but the speed of recovery varies with baseline CD4 and the timing of ART initiation.
The pathogenesis of HIV-associated hematological and immunological abnormalities combines the direct effects of HIV and immune-mediated secondary effects, affecting multiple systems.
Molecular mechanisms of CD4+ T-cell loss: HIV directly destroys CD4+ T cells after viral replication within them. Virus-infected and uninfected cells fuse through gp120–CD4 binding to form giant cells (syncytia), and these giant cells die by apoptosis. Bystander apoptosis: uninfected CD4+ T cells are also exposed to HIV proteins (gp120, Tat, Vpr), inducing apoptosis. Pyroptosis: the caspase-1 pathway activated by HIV causes inflammatory cell death of CD4+ T cells.
Mechanisms of bone marrow suppression: HIV infects hematopoietic stem cells and progenitor cells, which express CD4 at low levels, directly reducing hematopoietic capacity. The HIV Vpr protein induces cell-cycle arrest (G2 arrest) in hematopoietic progenitor cells. TNF-α and IL-1β inhibit the proliferation of CFU-GM (granulocyte–macrophage colony-forming units) and BFU-E (erythroid burst-forming units). Overexpression of hepcidin in chronic disease causes sequestration of iron in the reticuloendothelial system, producing functional iron-deficiency anemia.
Mechanism of autoimmune thrombocytopenia (ITP): HIV gp120 has structural similarity to platelet surface GPIIb/IIIa (integrin αIIbβ3), so antiplatelet autoantibodies are produced by molecular mimicry. These autoantibodies (IgG) bind to platelets, and splenic macrophages phagocytose them through Fc receptors, destroying the platelets. The mechanism of passive adsorption, in which HIV immune complexes bind to the platelet surface, also contributes.
Mechanism of chronic immune activation: collapse of gut immunity from HIV infection → bacterial translocation → elevated serum LPS → TLR4 stimulation → activation of monocytes and dendritic cells → systemic immune activation. This chronic immune activation causes chronic exhaustion of CD8+ T cells and accelerates aging of hematopoietic stem cells. Persistent immune activation leads to increased energy expenditure, shortened blood cell lifespan, and exhaustion of bone marrow hematopoietic function.
The clinical symptoms of HIV-associated hematological and immunological abnormalities vary according to the type and severity of the abnormality.
Symptoms of anemia: fatigue and generalized weakness are most common and markedly reduce the ability to perform daily activities. Pallor (conjunctivae, oral mucosa, palms), exertional dyspnea, palpitations, and headache occur. In severe anemia (Hb <8 g/dL), dyspnea at rest, angina (reduced coronary reserve), and symptoms of heart failure can occur. The faster the fall in Hb, the more severe the symptoms.
Symptoms of thrombocytopenia: mild thrombocytopenia (platelets 50,000–100,000/μL) is mostly asymptomatic but bleeding time is prolonged. Platelets 20,000–50,000/μL: bleeding persists for a long time even with minor trauma, and gum bleeding and nosebleeds occur. Platelets <20,000/μL: spontaneous petechiae, purpura, subcutaneous bleeding, nosebleeds, and gum bleeding occur spontaneously. Intracerebral hemorrhage (risk at platelets <10,000/μL) is not uncommon.
Symptoms of neutropenia: neutrophils <1,000/μL: recurrent bacterial infections (skin, mouth, anus), fever. Neutrophils <500/μL: sharply increased risk of severe bacterial infection; sepsis without fever is possible. Oral candidiasis and oral ulcers are common in neutropenia.
Symptoms of immunodeficiency: opportunistic infections due to decreased CD4 (oral candidiasis, herpes zoster, recurrent bacterial pneumonia). Increased vulnerability to encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae) due to reduced B-cell function. Hypergammaglobulinemia itself is mostly asymptomatic, but as nonfunctional antibody production increases, the efficiency of immune defense paradoxically decreases.
Physical examination findings: anemia: pale conjunctivae, oral mucosa, and palms, tachycardia, systolic murmur (flow murmur). Thrombocytopenia: skin petechiae (red spots the size of a pinhead), purpura, subcutaneous hematoma. Lymphadenopathy (with PGL). Hepatosplenomegaly (with opportunistic infection or direct HIV effect).
Blood test findings: complete blood count (CBC): decreased Hb, decreased platelets, decreased white blood cells. Peripheral blood smear: normocytic normochromic anemia (chronic disease), macrocytic (AZT toxicity), microcytic hypochromic (iron deficiency). Thrombocytopenia: nonspecific (autoantibody-mediated ITP or bone marrow suppression). Decreased segmented neutrophils, decreased lymphocytes.
Immunological test findings: CD4+ T-cell count: degree of decrease reflects the severity of immunodeficiency. CD4/CD8 ratio: inverted from normal 1.5–2.0 to <0.5. Quantitative HIV RNA: positive. Serum immunoglobulins (IgG, IgA, IgM): polyclonal hypergammaglobulinemia. β₂-microglobulin: elevated, reflecting the degree of immune activation. sCD14, sCD163: markers of monocyte activation, elevated.
Bone marrow examination findings: bone marrow examination is performed for cytopenia of unknown cause or suspected bone marrow involvement by opportunistic infection. Early HIV-associated marrow abnormalities: dysplastic changes, hypercellularity. Late: hypocellularity, fibrosis. MAC or tuberculous marrow involvement: granuloma formation. CMV marrow infection: cells containing intranuclear inclusions are observed.
Screening for hematological and immunological abnormalities in HIV-infected individuals should be performed regularly at every outpatient visit.
Basic blood tests (regular): complete blood count with differential: Hb, platelets, white blood cells, and neutrophils are measured regularly. Generally performed every 1–3 months after ART initiation and every 6 months once stable. CD4+ T-cell count and CD4/CD8 ratio: measured regularly before and after ART initiation. Quantitative HIV RNA test: monitors ART effect and is an indirect indicator of immune abnormalities.
Evaluation of the cause of anemia: when Hb is decreased, reticulocyte count and peripheral blood smear. Assess iron status with serum iron (Fe), total iron-binding capacity (TIBC), and serum ferritin. Screen for nutritional deficiency anemia with serum vitamin B12 and folate. Assess for reduced responsiveness with erythropoietin (EPO) level. Screen for autoimmune hemolytic anemia (AIHA) with the Coombs test (direct/indirect).
Evaluation of the cause of thrombocytopenia: when platelets <100×10⁹/L, antiplatelet autoantibody (anti-GPIIb/IIIa IgG) test. ADAMTS13 activity measurement to differentiate thrombotic thrombocytopenic purpura (TTP). Liver function tests (thrombocytopenia from increased splenic sequestration in cirrhosis). Exclude heparin-induced thrombocytopenia (HIT) (if on heparin). Bone marrow examination (when cytopenia is multilineage or after excluding other causes).
Immunological screening: serum IgG, IgA, IgM (assessment of hypergammaglobulinemia). Assess functional antibody response with vaccine antibody titers (Streptococcus pneumoniae, hepatitis B, etc.). Assess the degree of chronic immune activation with sCD14, CRP, and IL-6 (if needed).
Diagnosis of B23.2 consists of confirming HIV infection + identifying the cause of each hematological and immunological abnormality.
Diagnosis of CD4 immunodeficiency: CD4 <500/μL: moderate immunodeficiency. CD4 <200/μL: AIDS-defining immunodeficiency. CD4 <50/μL: severe immunodeficiency, risk of multiple opportunistic infections. CD4 is quantified by flow cytometry, and results are reported as an absolute number (cells/μL) and a percentage (%).
Diagnosis of HIV-associated anemia: confirmation of HIV infection + decreased Hb (men <13 g/dL, women <12 g/dL). Morphological classification of anemia: normocytic (chronic disease, bone marrow suppression), macrocytic (AZT, vitamin B12/folate deficiency), microcytic (iron deficiency). Classify the cause with iron studies, reticulocyte count, and the Coombs test. Bone marrow examination (when multilineage cytopenia or opportunistic infection is suspected).
Diagnosis of HIV-associated ITP: HIV infection + platelets <100×10⁹/L + exclusion of other causes (drugs, TTP, cirrhosis, etc.). Peripheral blood smear confirms thrombocytopenia and normal platelet morphology. Positive antiplatelet autoantibodies support the diagnosis, but a clinical diagnosis is possible even if negative. Bone marrow: normal, or megakaryocytes normal or increased.
Diagnosis of hypergammaglobulinemia: polyclonal hypergammaglobulinemia confirmed on serum protein electrophoresis (SPEP). Serum IgG >1,600 mg/dL, IgA >400 mg/dL, IgM >300 mg/dL (above general reference values). If a monoclonal protein (M spike) is present, exclude plasma cell neoplasms (multiple myeloma, monoclonal gammopathy of undetermined significance).
Treatment of HIV-associated hematological and immunological abnormalities is based on ART, together with specific treatment of each hematological abnormality.
ART initiation and optimization: immediate ART initiation in all HIV-infected individuals is most effective for immune recovery, improvement of anemia, and improvement of ITP. Zidovudine (AZT) worsens anemia and neutropenia through bone marrow toxicity, so in patients with hematological abnormalities it is replaced with TAF- or TDF-based ART. HIV RNA suppression by ART reduces chronic immune activation and contributes to fundamental improvement of blood abnormalities.
Treatment of anemia: erythropoietin (EPO) alfa or darbepoetin alfa: effective when serum EPO <500 IU/L. Start with EPO 40,000 IU/week subcutaneously. Iron-deficiency anemia: oral iron supplementation (ferrous sulfate 300 mg three times daily) or intravenous iron (if oral intolerance). Vitamin B12 deficiency: cyanocobalamin 1,000 μg intramuscularly or high-dose oral (1,000–2,000 μg/day). Folate deficiency: folic acid 1–5 mg/day orally. Severe anemia (Hb <7–8 g/dL, symptomatic): consider red blood cell transfusion.
Treatment of ITP: platelets often recover spontaneously after ART initiation. Platelets <30,000/μL or bleeding symptoms: IVIG (intravenous immunoglobulin) 1 g/kg/day for 2 days (to acutely raise platelets). Prednisolone 1 mg/kg/day (4–6 weeks, gradual taper). Eltrombopag: TPO receptor agonist, effective in chronic ITP. Rituximab 375 mg/m² once weekly × 4: steroid-refractory ITP. Severe bleeding (platelets <10,000/μL or risk of intracerebral hemorrhage): platelet transfusion + IVIG combined.
Treatment of neutropenia: reduce the dose of or stop bone-marrow-toxic drugs (AZT, TMP-SMX, ganciclovir). G-CSF (filgrastim) 5 μg/kg/day subcutaneously: for severe neutropenia (<500/μL) or recurrent bacterial infections. Prophylactic G-CSF is not routinely recommended and is considered in patients with hematologic malignancy during chemotherapy.
The prognosis of HIV-associated hematological and immunological abnormalities varies according to the response to ART and the type of each abnormality.
Anemia and prognosis: anemia is an independent predictor of mortality in HIV-infected individuals. The risk of death in HIV-infected individuals with anemia is 2–4 times higher than in patients without anemia. Correction of anemia by ART is associated with improved survival. However, if anemia persists after the introduction of ART, the prognosis is relatively poor.
CD4 recovery and prognosis: the pattern of CD4 recovery after ART initiation is directly linked to prognosis. The higher the CD4 level at ART initiation, the faster and more complete the CD4 recovery. Immunological non-responders: patients in whom HIV RNA is suppressed by ART but CD4 remains at 200/μL or below (about 10–15%) have a poor long-term prognosis. Chronic immune activation persists even after ART and contributes to the development of cardiovascular, renal, and neurological non-AIDS complications.
ITP and prognosis: most HIV-associated ITP improves after ART and is rarely life-threatening. However, in severe ITP (platelets <10,000/μL), intracerebral hemorrhage is fatal. Chronic ITP is a marker of persistent immune dysregulation, which may be associated with the risk of lymphoma.
Early HIV diagnosis and ART: the most effective prevention of hematological and immunological abnormalities is early HIV diagnosis and immediate ART initiation to prevent CD4 decline. The earlier ART is started at a high CD4 level, the lower the severity of cytopenias and immune dysregulation.
Avoiding bone-marrow-toxic drugs: zidovudine (AZT) causes bone marrow suppression and anemia, so it is excluded from first-line ART choices in current guidelines. TAF/TDF-based ART has markedly lower hematological toxicity. To prevent cytopenias due to drug toxicity, the hematological toxicity profile is considered when choosing ART drugs.
Maintaining nutritional status: preventing iron, vitamin B12, and folate deficiency prevents nutritional deficiency anemia. Regular nutritional assessment and, when needed, supplementation in HIV-infected individuals reduce hematological complications.
Prevention of opportunistic infections: PCP prophylaxis (TMP-SMX) is needed at CD4 <200/μL, but because TMP-SMX itself can cause cytopenias, the dose and indications are set carefully. Prophylactic treatment according to CD4 level is given appropriately to prevent bone marrow involvement by opportunistic infections (MAC, CMV).
Regular monitoring: even during ART, CBC and CD4 counts are measured every 6 months for early detection of hematological abnormalities. If severe cytopenia newly develops, immediately evaluate for ART drug toxicity, new opportunistic infection, or malignancy.